Humacyte (HUMA) Assets (2020 - 2026)

Humacyte (HUMA) has reported Assets for 7 consecutive years, with $138.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets fell 0.51% year-over-year to $138.1 million in Q2 2026; TTM through Jun 2026 was $138.1 million, a 0.51% decrease from a year earlier, with the FY2025 full-year figure at $116.4 million, down 15.6% from the prior year.
• Assets was $138.1 million for Q2 2026 at Humacyte, up from $110.6 million in the prior quarter.
• Over five years, Assets peaked at $264.5 million in Q1 2022 and troughed at $91.5 million in Q3 2025.
• A 5-year average of $160.0 million and a median of $144.1 million in 2023 frame the typical range for Assets.
• Across the five-year window, Assets surged 162.71% in 2022 and sank 37.24% in 2023, its largest moves.
• Over 5 years, Assets stood at $204.3 million in 2022, then slumped by 37.24% to $128.2 million in 2023, then rose by 7.53% to $137.9 million in 2024, then declined by 15.6% to $116.4 million in 2025, then advanced by 18.67% to $138.1 million in 2026.
• The last three Assets figures came in at $138.1 million (Q2 2026), $110.6 million (Q1 2026), and $116.4 million (Q4 2025), per Business Quant data.